Ralf M. Zwacka, Yulong Zhang, Weihong Zhou, Jeff Halldorson, John F. Engelhardt – 30 December 2003 – For many inherited and acquired hepatic diseases, liver transplantation is the only possible therapeutic strategy. Ischemia/reperfusion (I/R) damage to donor tissue is thought to be one component that may play a role in the decline of posttransplant tissue function and ultimately rejection. The transcription factors, AP‐1 and nuclear factor κB (NF‐κB), play important roles in the acute cellular responses to tissue damage, as well as the inflammatory phase following I/R.

Paul Calès, Frédéric Oberti, Nary Veal, Joël Fort, Mehdi Kaassis, Frédéric Moal, Christophe Aubé, Eric Vuillenin, Christophe Pilette, Hervé Rifflet, Renaud Trouvé – 30 December 2003 – The aim of this study was to develop a technique that could serve as an index of portosystemic shunt (PSS) blood flow in portal hypertensive rats whose main shunt is the splenorenal shunt (SRS). The main hemodynamic measurements performed were: SRS blood flow by the transit‐time ultrasound (TTU) method, percentage of PSS, and regional blood flows by the microsphere method.

Kazuo Shimada, Javier Navarro, Douglas E. Goeger, Shamimunisa B. Mustafa, Paul H. Weigel, Steven A. Weinman – 30 December 2003 – The liver plays a major role in metabolism and elimination of leukotrienes (LT). It produces cysteinyl leukotrienes (cLT), and cLT have been implicated in hepatocellular toxicity in several models of lipopolysaccharide (LPS)‐associated liver injury.

K. Sandy Pang, Pi Jun Wang, Alfred Y. Chung, Allan W. Wolkoff – 30 December 2003 – Oatp1, the organic anion transport polypeptide, is an integral membrane protein cloned from rat liver that mediates the uptake of various organic anions such as bromosulfophthalein (BSP) and taurocholate (TCA). Recent studies by others revealed that the thrombin inhibitor, CRC 220, a modified dipeptide, was transported by oatp1. The present study was designed to examine whether another modified peptide, enalapril, an angiotensin‐converting enzyme inhibitor, was also a substrate.

Karine Mahéo, Fabrice Morel, Jocelyne Antras‐Ferry, Sophie Langouët, Fabienne Desmots, Laurent Corcos, André Guillouzo – 30 December 2003 – The effect of Escherichia coli lipopolysaccharide (LPS), a classic inducer of the acute‐phase response, has been analyzed on both constitutive and oltipraz (a chemoprotective agent)‐inducible messenger RNAs (mRNAs) and enzyme activities of major cytochromes P450 (CYPs) and glutathione transferases (rGSTs) in rat liver.

Jean‐Louis Payen, Jacques Izopet, Virginie Galindo‐Migeot, Valérie Lauwers‐Cances, Jean‐Pierre Zarski, Jean‐Marie Seigneurin, Elizabeth Dussaix, Jean‐Jacques Voigt, Janick Selves, Karl Barange, Jacqueline Puel, Jean‐Pierre Pascal, Le Groupe D'étude et De Traitement du Virus De L'hépatite C (Get.vhc) – 30 December 2003 – We studied the efficacy of three interferon alfa‐2b (IFN‐α2b) regimens for the retreatment of patients with chronic hepatitis C (CHC) with prior complete response followed by relapse.

Jacquelyn J. Maher – 30 December 2003

M. Eugenia Guicciardi, Gregory J. Gores – 30 December 2003

C Tibbs, P Donaldson, J Underhill, L Thomson, K Manabe, R Williams – 1 December 1996 – In the search for factors which may influence susceptibility to and outcome from chronic hepatitis C virus (HCV) infection, few studies have considered the influence of host genes. In the present investigation we have performed HLA DRB1, DQA1, DQB1, and DPB1 genotyping on 104 northern European patients with chronic HCV infection and 177 racially and geographically matched controls.

J S McMillan, D S Bowden, P W Angus, G W McCaughan, S A Locarnini – 1 December 1996 – Recurrent hepatitis B virus (HBV) infection is a major problem in patients undergoing liver transplantation. Previously, we reported that infection with HBV strains containing a mutation in the precore region (G‐to‐A at nucleotide 1896) was associated with severe recurrent disease posttransplantation. In this study we investigated other mutations in the precore/core gene and core promoter which may be associated with this severe recurrence.